RxDoctor Payments Data

Albert Deloskey, MD

Internal Medicine · Towson, MDNPI 1891750493

Payments from drug & device makers

$8,835in general payments, 2019–2025

Across 406 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$989
  • Sanofi-aventis U.S. LLC$812
  • AstraZeneca$754
  • GSK$620
  • Novartis$508
  • plus $4K from 32 others

What the payments were for

  • Food & beverage$8,76499%
  • Education$721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,835 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$286,494
Medicare patients
529
Services billed
3,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin70$101,155
EliquisApixaban70$86,264
OzempicSemaglutide32$45,208
KerendiaFinerenone40$43,316
FarxigaDapagliflozin Propanediol27$38,653
MounjaroTirzepatide25$30,653
JanuviaSitagliptin Phosphate18$28,311
TrulicityDulaglutide20$28,050
XareltoRivaroxaban17$22,755
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$20,937
JanumetSitagliptin Phos/Metformin Hcl14$20,008
TradjentaLinagliptin16$18,228
Repatha SureclickEvolocumab11$18,083
Rosuvastatin Calcium723$17,944
Atorvastatin Calcium775$13,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$345$119,38386 claims
PfizerEliquis, Paxlovid$480$89,07389 claims
Lilly USA, LLCMounjaro, Trulicity$266$58,70345 claims
MerckJanuvia, Janumet$394$48,31932 claims
Novo NordiskOzempic$1,173$45,20832 claims
BayerKerendia$79$43,31640 claims
AstraZenecaFarxiga$754$38,65327 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$620$35,96142 claims
Astellas Pharma US IncMyrbetriq$449$13,43113 claims
Esperion Therapeutics, Inc.Nexletol$46$10,87611 claims
AbbVieSynthroid$989$4,825104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →